Syndax Pharmaceuticals (STU:1T3) Moat Score: 4/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1T3 Syndax Pharmaceuticals Inc STU:1T3
34 GF Score
Price €19.84
GF Value €698.80
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Moat Score?

Syndax Pharmaceuticals STU:1T3 -3.27% 34 Moat Score is 4 as of Jul. 17, 2026. GuruFocus rates STU:1T3 with a GF Score™ of 34/100 and a GF Value™ of €698.80 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,396 Biotechnology companies, Syndax Pharmaceuticals ranks better than 88.75% on this metric.

Syndax Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Syndax Pharmaceuticals has Narrow Moat: Syndax Pharmaceuticals has valuable intellectual property and patents in the biotech sector. However, the company faces significant competition and regulatory hurdles, limiting its market leadership and pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Syndax Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Syndax Pharmaceuticals  (STU:1T3) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Syndax Pharmaceuticals Moat Score Related Terms

STU:1T3 vs IOVA, GLUE, TYRA: Moat Score Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Moat Score falls into.


STU:1T3
34GF Score
Syndax Pharmaceuticals Inc STU:1T3
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Syndax Pharmaceuticals (STU:1T3) has a Moat Score of 4 as of Jul. 17, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Syndax Pharmaceuticals ranks #157 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Syndax Pharmaceuticals' Moat Score too high?
Syndax Pharmaceuticals' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Syndax Pharmaceuticals' value of 4 is 100% above this industry median. Based on the distribution chart, Syndax Pharmaceuticals ranks #157 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Moat Score compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #157 out of 1396 companies for Moat Score. This places Syndax Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Syndax Pharmaceuticals' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syndax Pharmaceuticals's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Syndax Pharmaceuticals (STU:1T3) is currently considered Possible Value Trap. The stock's GF Value™ is €698.80, compared to a current price of €19.84 — trading 97.2% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Syndax Pharmaceuticals' overall GF Score™ is 34/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Syndax Pharmaceuticals (STU:1T3), the current Moat Score is 4 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syndax Pharmaceuticals (STU:1T3) Overvalued in 2026?

Based on GuruFocus' analysis, Syndax Pharmaceuticals stock appears to be undervalued. The current stock price of €19.84 is trading 97.2% below its estimated GF Value™ of €698.80. GuruFocus considers Syndax Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:1T3:

  • Moat Score: 4
  • GF Value™: €698.80 vs. price of €19.84 (97.2% below fair value)
  • GF Score™: 34/100 with 9 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1396)

No single metric tells the full story. See the STU:1T3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
34GF Score

Get the complete analysis for STU:1T3

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.84
Price
€698.80
GF Value